MA39227A1 - Heteroaryl amides as inhibitors of protein aggregation - Google Patents
Heteroaryl amides as inhibitors of protein aggregationInfo
- Publication number
- MA39227A1 MA39227A1 MA39227A MA39227A MA39227A1 MA 39227 A1 MA39227 A1 MA 39227A1 MA 39227 A MA39227 A MA 39227A MA 39227 A MA39227 A MA 39227A MA 39227 A1 MA39227 A1 MA 39227A1
- Authority
- MA
- Morocco
- Prior art keywords
- disease
- protein aggregation
- methods
- inhibitors
- parkinson
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne certains composés d'amide hétéroaryles, des compositions pharmaceutiques les contenant et des procédés d'utilisation associés, notamment des procédés permettant de prévenir, inverser, ralentir et inhiber l'agrégation protéique, et des procédés permettant de traiter des maladies qui sont associées à l'agrégation protéique, notamment les maladies neurodégénératives telles que la maladie de parkinson, la maladie d'alzheimer, la maladie du corps de lewy, la maladie de parkinson avec démence, la démence fronto-temporale, la maladie de huntington, la sclérose latérale amyotrophique et l'atrophie multisystématisée, et le cancer et le mélanome.The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them and methods of use thereof, including methods of preventing, reversing, slowing down and inhibiting protein aggregation, and methods of treating diseases that are associated with protein aggregation, including neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Lewy's body disease, Parkinson's disease with dementia, Frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis and multisystematous atrophy, and cancer and melanoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461933246P | 2014-01-29 | 2014-01-29 | |
| PCT/US2015/013263 WO2015116663A1 (en) | 2014-01-29 | 2015-01-28 | Heteroarly amides as inhibitors of protein aggregation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA39227A1 true MA39227A1 (en) | 2017-09-29 |
| MA39227B1 MA39227B1 (en) | 2018-04-30 |
Family
ID=58698445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39227A MA39227B1 (en) | 2014-01-29 | 2015-01-28 | Heteroaryl amides as inhibitors of protein aggregation |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR099208A1 (en) |
| MA (1) | MA39227B1 (en) |
-
2015
- 2015-01-28 AR ARP150100239A patent/AR099208A1/en unknown
- 2015-01-28 MA MA39227A patent/MA39227B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA39227B1 (en) | 2018-04-30 |
| AR099208A1 (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41013A (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| PH12016501493A1 (en) | Heteroaryl amides as inhibitors of protein aggregation | |
| MX2018005600A (en) | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor. | |
| SA519400950B1 (en) | Compositions and Methods of Inhibiting MASP-3 for The Treatment of Various Diseases and Disorders | |
| MX2019007480A (en) | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation. | |
| GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
| MA40240A (en) | HETERARYL KINASE INHIBITION COMPOUNDS | |
| MX2019003805A (en) | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies. | |
| MX2019004859A (en) | Combination treatments comprising administration of imidazopyrazinones. | |
| PH12018500659A1 (en) | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof | |
| EA201991755A1 (en) | Bicyclic bisheteroaryl derivatives as protein aggregation modulators | |
| MX2019007053A (en) | Bis-heteroaryl derivatives as modulators of protein aggregation. | |
| MX2015000618A (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation. | |
| MY184878A (en) | Compositions and methods for treating neurodegenerative diseases | |
| MX2019001634A (en) | Amide compounds, pharmaceutical compositions thereof, and methods of using the same. | |
| MX2018001592A (en) | Compositions and methods for treating and preventing neurodegenerative disorders. | |
| EA201991753A1 (en) | Alcoxybisheteroaryl derivatives as protein aggregation modulators | |
| MX2019008603A (en) | A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease. | |
| MX2020006140A (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions. | |
| EP3610879A4 (en) | Composition for treatment and/or prevention of alzheimer's disease | |
| MA39227A1 (en) | Heteroaryl amides as inhibitors of protein aggregation | |
| EP3773500A4 (en) | Compositions and methods of detecting and treating alzheimer's disease |